Methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway
US11629192B2 · kind B2 · utility
0Cited by
0References
4Claims
0Family size
Assignees
- INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
- UNIVERSITÉ PARIS CITÉ
- Moraine Corporation
- ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP)
- CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
- UNIVERSITE GRENOBLE ALPES
- COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
- UNIVERSITÉ DE BOURGOGNE
Inventors
Key dates
| Filing date | Sep 4, 2018 |
| Grant date | Apr 18, 2023 |
| Priority date | — |
| Expiry date | May 17, 2039 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.